drugset / Trial / NCT03140358

The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)

NCT03140358

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study of low dose atropine in preventing the onset and progression of myopia in high risk children with pre-myopia or low-myopia.

Timeline

Start
2017-04-21
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atropine Other / unclassified 0.01 %

Indications